Reducing Immune Checkpoint Inhibitor Discontinuation in Dermatomyositis May Improve Survival: A Systematic Review Supplementary Materials
Published: 21 May 2026| Version 1 | DOI: 10.17632/4sgkyg6rn2.1
Contributors:
, , , , Description
Reducing Immune Checkpoint Inhibitor Discontinuation in Dermatomyositis May Improve Survival: A Systematic Review Supplementary Materials including Supplementary Methods, Supplementary Figure S1, Supplementary Table S1, Supplementary Table S2, and Supplementary Figure S2
Files
Steps to reproduce
See supplementary methods for details.
Institutions
- NYU Langone HealthNew York, New York
Categories
Autoimmunity, Adverse Effect of Drug, Dermatomyositis, Cutaneous Paraneoplastic Syndrome, Interstitial Lung Disorder, Immune Checkpoint Inhibitor